Gland Pharma Limited (NSE:GLAND) Annual Report 2025



The latest annual report of Gland Pharma Limited (GLAND) was published on 31 Mar 2025. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - GLAND Annual Results

Amounts in INR

Total Revenue
₹56.17B
Gross Profit
₹35.98B
EBIT
₹11.80B
Net Tangible Assets
₹95.64B
Net Income
₹6.99B
Capital Expenditures
-

GLAND Income Statement 2025 Annual Report

As per the latest Income Statement of GLAND, the Net revenue decreased by ₹-482.18M (-1%) compared to the previous period. The operating income in 2025 increased by - (-). The net income as per the annual report was ₹6.99B which decreased by ₹-739.34M (-10%) compared to previous year.

Income Statement Report (2025/2024)

2025 2024
Total Revenue ₹56.17B ₹56.65B
Gross Profit ₹35.98B ₹35.98B
Operating Income - -
Income Before Tax - -
Net Income ₹6.99B ₹7.72B

Balance Sheet - GLAND 2025 Annual Report

Read further: GLAND Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Gland Pharma Limited showed the company increased the cash on balance sheet by ₹0.00 (0%). The Net tangible assets of GLAND on the balance sheet were at ₹95.64B which is ₹0.00 (0%) more than previous annual report. The total stockholder equity also increased by - (-) compared to previous reporting period.

Balance Sheet Statement Report (2025/2024)

2025 2024
Cash ₹32.02B ₹32.02B
Total Assets - -
Long Term Debt - -
Total Liabilities ₹3.02B ₹3.02B
Total Shareholder Equity - -
Net Tangible Assets ₹95.64B ₹95.64B

Cash Flow Statement - GLAND 2025 Annual Report

The 2025 annual cash flow statement of Gland Pharma Limited showed that the net income decreased by ₹-739.34M (-10%) compared to previous reporting period. Also the capital expenditure of GLAND increased by - (-).

As of 2025, the total cash from investing activities was - and total cash from financing activities was -.

Cash Flow Statement Report (2025/2024)

2025 2024
Net Income ₹6.99B ₹7.72B
Capital Expenditures - -
Dividends Paid - -
Total Cash From From Investing Activities - -
Total Cash From From Financing Activities - -

Gland Pharma Limited Annual Report History

Income Statement

Income Statement history of Gland Pharma Limited (NSE:GLAND)

31 Mar 2025 31 Mar 2024 31 Mar 2023 31 Mar 2022
Total Revenue ₹56.17B ₹56.65B ₹36.25B ₹44.01B
Cost Of Revenue ₹0.00 ₹0.00 ₹0.00 ₹0.00
Gross Profit ₹0.00 ₹0.00 ₹0.00 ₹0.00
Research Development - - - -
Selling General Administrative - - - -
Non Recurring - - - -
Other Operating Expenses - - - -
Total Operating Expenses ₹0.00 ₹0.00 ₹0.00 ₹0.00
Operating Income - - - -
Total Other Income Expense Net - - - -
Ebit ₹0.00 ₹0.00 ₹0.00 ₹0.00
Interest Expense - - - -
Income Before Tax - - - -
Income Tax Expense ₹0.00 ₹0.00 ₹0.00 ₹0.00
Minority Interest - - - -
Net Income From Continuing Ops - - - -
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income ₹6.99B ₹7.72B ₹7.81B ₹12.12B
Net Income Applicable To Common Shares - - - -

Balance Sheet Statement

Balance Sheet Statement history of Gland Pharma Limited (NSE:GLAND)

31 Mar 2025 31 Mar 2024 31 Mar 2023 31 Mar 2022
Cash ₹32.02B ₹32.02B - -
Total Assets - - - -
Total Liab ₹3.02B ₹3.02B - -
Long Term Debt - - - -
Total Stockholder Equity - - - -
Net Tangible Assets ₹95.64B ₹95.64B - -

Cash Flow Statement

Cash Flow Statement history of Gland Pharma Limited (NSE:GLAND)

31 Mar 2025 31 Mar 2024 31 Mar 2023 31 Mar 2022
Net Income ₹6.99B ₹7.72B - -
Capital Expenditures - - - -
Dividends Paid - - - -
Total Cashflows From Investing Activities - - - -
Total Cash From Financing Activities - - - -